Portal de investigación
Subprotocol A A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
REVOLUTION MEDICINES, INC.
Cita
Subprotocol A A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS Mutated Non-Small Cell Lung Cancer (NSCLC). (RMC-LUNG-101 subprotocolo A). Revolution Medicines, Inc. 2024IP:ÓSCAR JOSÉ JUAN VIDAL.